Institution Directory

Clinical trials at City of Hope

Sites in Duarte, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:36 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1042

Shown on this page

Current sort

Live official records

Conditions: CRC (Colorectal Cancer)
Interventions: cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation); Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: CRC (Colorectal Cancer)
Interventions: cfDNA 5mC/5hmC Sequencing (EpiCORE Discovery Phase), EpiCORE Assay (Targeted Sequencing / qPCR Validation); Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Primary Liver Cancer, Primary Liver Carcinoma, Hepatic Cancer, Hepatic Carcinoma
Interventions: ELUCIDATE; Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
Interventions: 225Ac-PSMA-Trillium (BAY3563254); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 4
States / cities: Duarte, California • Minneapolis, Minnesota • Omaha, Nebraska + 1 more

Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, Colorectal Cancer Stage I, Colorectal Cancer Stage IV, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Colorectal Neoplasms Malignant
Interventions: ENCODE; Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Gastric Cancer
Interventions: small RNA-seq or array, ENLIGHT Assay; Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Basiliximab, Fludarabine Phosphate, Indium In 111-DOTA-Basiliximab, Melphalan, Palifermin, Total Lymphoid Irradiation, Total Marrow Irradiation, Yttrium Y 90 Basiliximab; Procedure · Biological · Drug + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Marginal Zone Lymphoma
Interventions: Rituximab, Venetoclax; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 8
States / cities: Duarte, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
Interventions: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs); Drug
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: Not listed
Enrollment: 99,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2041
U.S. locations: 142
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Interventions: JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax; Biological
Lead sponsor: Juno Therapeutics, a Subsidiary of Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 83
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Interventions: NX-5948; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Duarte, California • San Francisco, California • Denver, Colorado + 15 more

Conditions: Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 493
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more

About this City of Hope institution page

What this page lists: ClinicalTrials.gov records that list City of Hope in Duarte, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at City of Hope

Filter and sort this campus

Live official records

Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC

cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Early Onset Colorectal Cancer Detection

Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

About this City of Hope institution page